Quantum chemical optimization and residue-specific stabilization of CDK20 inhibitors in hepatocellular carcinoma
Ahmed I Foudah1, Mohammed H Alqarni1, Tariq M Aljarba1
1Department of Pharmacognosy, College of Pharmacy, Prince Sattam Bin Abdulaziz University, 11942, Al Kharj, Saudi Arabia.
Abstract:
Cyclin-dependent kinase 20 (CDK20), also known as cell cycle-related kinase (CCRK), plays a pivotal role in hepatocellular carcinoma (HCC) progression by regulating β-catenin signaling and promoting uncontrolled proliferation. Despite its emerging significance, selective small-molecule inhibitors of CDK20 remain unexplored. In this study, a known CDK20 inhibitor, ISM042-2-048, was employed as a reference to retrieve structurally similar compounds from the PubChem database using an 85% similarity threshold. Out of 6,235 candidates, the top three compounds (153295720, 145037521, and 163292314) were shortlisted through MTiOpenScreen-based virtual screening. Geometry optimizations using density functional theory (B3LYP/cc-pVDZ) refined each ligand's electronic properties before re-docking against the AlphaFold-derived CDK20 structure. 153295720 exhibited the highest binding affinity (- 11.8 kcal/mol), engaging critical active-site residues such as Met84, Lys33, Ala131, and Asp145 through polar and hydrophobic interactions. Molecular dynamics simulations (500 ns) confirmed the complex's structural stability, with 153295720 showing the lowest RMSD and RMSF fluctuations and highly persistent hydrogen bonding. MM/GBSA analysis further supported its superiority, revealing the most favorable binding energy (- 69.09 ± 8.29 kcal/mol), dominated by van der Waals and electrostatic interactions. Free energy landscape analysis revealed a single dominant basin, and superimposition of MD-derived minima with the docked pose yielded an RMSD of 1.464 Å, supporting pose fidelity. Comparatively, the reference compound displayed greater conformational drift and reduced energetic convergence. This integrative computational approach establishes 153295720 as a structurally and dynamically superior inhibitor, capable of stabilizing key catalytic residues of CDK20. These findings provide a rational basis for the biochemical targeting of CDK20 in HCC and highlight residues essential for selective inhibition, paving the way for experimental validation and lead optimization.
Insights
Researchers identified a novel compound, 153295720, as a potent inhibitor of Cyclin-dependent kinase 20 (CDK20). This discovery offers a promising strategy for targeting hepatocellular carcinoma (HCC) by stabilizing key CDK20 residues.
Area of Science:
- Oncology
- Biochemistry
- Computational Chemistry
Background:
- Cyclin-dependent kinase 20 (CDK20/CCRK) is implicated in hepatocellular carcinoma (HCC) progression.
- CDK20 regulates beta-catenin signaling and cell proliferation in HCC.
- Selective small-molecule inhibitors for CDK20 are currently lacking.
Purpose of the Study:
- To identify novel small-molecule inhibitors of CDK20.
- To computationally screen and validate potential CDK20 inhibitors.
- To provide a basis for experimental targeting of CDK20 in HCC.
Main Methods:
- Virtual screening of PubChem database for compounds similar to a known CDK20 inhibitor.
- Structure-based virtual screening using MTiOpenScreen and docking against AlphaFold-predicted CDK20.
- Geometry optimization via density functional theory (B3LYP/cc-pVDZ).
- Molecular dynamics (MD) simulations (500 ns) and MM/GBSA binding energy calculations.
- Free energy landscape analysis.
Main Results:
- Compound 153295720 demonstrated the highest binding affinity (-11.8 kcal/mol) to CDK20.
- 153295720 formed key interactions with active-site residues Met84, Lys33, Ala131, and Asp145.
- MD simulations confirmed the stability of the 153295720-CDK20 complex, with minimal fluctuations.
- MM/GBSA analysis yielded the most favorable binding energy (-69.09 ± 8.29 kcal/mol) for 153295720.
- The reference compound showed greater conformational drift compared to 153295720.
Conclusions:
- Compound 153295720 is a structurally and dynamically superior CDK20 inhibitor.
- This inhibitor effectively stabilizes critical catalytic residues of CDK20.
- Findings support the potential of 153295720 for HCC treatment and guide future experimental validation.
More Related Videos
06:38An Oncogenic Hepatocyte-Induced Orthotopic Mouse Model of Hepatocellular Cancer Arising in the Setting of Hepatic Inflammation and Fibrosis
Published on: September 12, 2019
12:24A Three-Dimensional Spheroid Model to Investigate the Tumor-Stromal Interaction in Hepatocellular Carcinoma
Published on: September 30, 2021
Related Concept Videos
Inhibition of Cdk Activity
M-Cdk Drives Transition Into Mitosis
Cyclin-dependent kinases, or Cdks, work in concert with cyclins to control cell cycle transitions. M-Cdk, a complex of Cdk1 bound to M cyclin, is a well-known example of this coordinated control that drives the transition from the G2 to the M phase.
M cyclin...
Combination Therapies and Personalized Medicine
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
Targeted Cancer Therapies
There are several types of targeted therapies against...
